29W14: Abstracts: Systemic Lupus Erythematosus – Treatment II (2693–2698)

Abstract Moderator(s)

• GA

  Graciela Alarcón, MD, MPH (she/her/hers)

  The University of Alabama at Birmingham
  Oakland, California, United States

  Disclosure information not submitted.
• 

  David Pisetsky, MD, PhD

  Duke University Medical Center
  Durham, NC, United States

  Disclosure information not submitted.

Please note: This session is not eligible for CME Credits.

Presentations:

• 11:30 AM - 11:45 AM Central Time

  A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-maintenance Treatment for Class III/IV±V Lupus Nephritis
  

  Presenting Author: Sandra Navarra, md, MD – University of Santo Tomas
• 11:45 AM - 12:00 PM Central Time

  Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
  

  Presenting Author: Amit Saxena, MD, MSc – NYU Grossman School of Medicine
• 12:00 PM - 12:15 PM Central Time

  B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
  

  Presenting Author: Carlo Tur, MD – Universitätsklinikum Erlangen - FAU Erlangen - Nürnberg
• 12:15 PM - 12:30 PM Central Time

  Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
  

  Presenting Author: Eric Morand, MD, PhD – Monash University
• 12:30 PM - 12:45 PM Central Time

  CAR T-cell Therapy in SLE: A Systematic Review
  

  Presenting Author: Alberto Nordmann-Gomes, BS – Columbia University Irving Medical Center
• 12:45 PM - 1:00 PM Central Time

  Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
  

  Presenting Author: YUN KYU KIM, MD – Seoul National University